|Company Name||# of Hedge Funds||# of Insiders Buying||# of Insiders Selling|
|Santarus, Inc. (NASDAQ:SNTS)||15||1||14|
|Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)||9||0||0|
|Sarepta Therapeutics Inc (NASDAQ:SRPT)||19||0||1|
|ImmunoGen, Inc. (NASDAQ:IMGN)||5||0||2|
|Acorda Therapeutics Inc (NASDAQ:ACOR)||10||0||7|
With the results demonstrated by our research, retail investors should always keep an eye on hedge fund and insider trading sentiment, and Nektar Therapeutics (NASDAQ:NKTR) shareholders fit into this picture quite nicely.